Single Photon Emission Computed Tomography (SPECT) is a nuclear medicine imaging technique that uses gamma-emitting radioactive tracers to visualize metabolic and molecular processes in the living brain. In neurodegenerative disease diagnosis, SPECT plays a crucial role particularly in evaluating dopaminergic function in Parkinson's disease and atypical parkinsonian syndromes including multiple system atrophy, progressive supranuclear palsy, and corticobasal syndrome.
- Radiopharmaceutical administration: Patient receives an intravenous injection of a gamma-emitting radiotracer
- Tracer uptake: The tracer accumulates in target tissues based on regional blood flow or specific receptor binding
- Gamma emission: The radioactive decay releases gamma photons
- Detection: Rotating gamma cameras detect photons from multiple angles
- Reconstruction: Tomographic algorithms create cross-sectional images showing tracer distribution
| Tracer |
Target |
Primary Use |
| [123I]FP-CIT (DaTscan) |
Dopamine transporter |
Parkinsonism differentiation |
| 99mTc-HMPAO |
Cerebral blood flow |
Perfusion imaging |
| 123I-ioflupane |
Dopamine transporter |
DaTscan for PD |
| 123I-IBZM |
Dopamine D2 receptors |
Receptor imaging |
The most clinically significant application of SPECT in neurodegeneration is dopamine transporter (DAT) imaging using [123I]FP-CIT (commercially known as DaTscan). This technique:
- Measures presynaptic dopaminergic integrity in the striatum
- Differentiates parkinsonian disorders from non-degenerative conditions like essential tremor[@daparte1999]
- Detects early Parkinson's disease even before clinical diagnosis
- Supports differential diagnosis between PD, MSA, PSP, and CBS
Cerebral blood flow SPECT using 99mTc-HMPAO provides information about:
Perfusion SPECT in CBS shows characteristic asymmetric patterns:
- Contralateral hypoperfusion to the more affected side
- Frontal and parietal cortex involvement
- Posterior cingulate preserved relative to other regions
PSP demonstrates:
- Midbrain hypoperfusion (relative to cerebellum)
- Posterior frontal and precentral gyrus involvement
- Reduced caudate perfusion
FTD variants show distinct patterns:
- Behavioral variant FTD: Frontotemporal hypoperfusion[@bvftd]
- Semantic dementia: Anterior temporal hypoperfusion
- Progressive aphasia: Left perisylvian hypoperfusion
| Feature |
SPECT |
PET |
| Resolution |
Lower (7-10mm) |
Higher (4-5mm) |
| Cost |
Lower |
Higher |
| Radiotracer half-life |
Longer-lived |
Shorter-lived |
| Dopamine imaging |
Excellent (DaTscan) |
Excellent |
| Amyloid imaging |
Limited |
Excellent (Pittsburgh compound B) |
| Tau imaging |
Limited |
Excellent |
| Availability |
More widely available |
Less available |
- Collimator: Low-energy high-resolution (LEHR) for optimal resolution
- Matrix: 128×128 or 256×256
- Angular rotation: 360° in 120 steps
- Acquisition time: 30-45 minutes
- Reconstruction: Filtered backprojection or iterative reconstruction
Quantitative measures include:
- Specific binding ratio (SBR): Striatal binding relative to non-specific binding
- Putamen-to-caudate ratio: Pattern analysis for specific disorders
- Asymmetry index: Useful for CBS and hemiparkinsonism
Key quality metrics:
- Count statistics: Minimum 1.5 million counts per acquisition
- Motion correction: Essential for accurate quantification
- Attenuation correction: Improves accuracy, especially in deep structures
SPECT DAT imaging is recommended when:
- Clinical diagnosis is uncertain between PD and non-parkinsonian tremor
- Suspicion of atypical parkinsonism (MSA, PSP, CBS)
- Early-onset Parkinson's with atypical features
- Drug-induced parkinsonism vs. PD differentiation
Perfusion SPECT helps differentiate:
- Alzheimer's disease: Posterior cingulate and precuneus hypoperfusion
- DLB: Occipital hypoperfusion (especially posterior)
- FTD: Frontotemporal hypoperfusion
In manganism, DaTscan shows preserved dopamine transporter binding, distinguishing it from Parkinson's disease[@kim2011]:
- Normal FP-CIT uptake in striatum
- Helps differentiate from classic Parkinsonian disorders
Novel DAT ligand with improved characteristics:
- Higher affinity for dopamine transporter
- Better signal-to-noise ratio
- Potential for better quantification
While technically a different modality, MIBG (metaiodobenzylguanidine) SPECT:
- Evaluates cardiac sympathetic innervation
- Supports DLB vs. AD differentiation
- Reduced uptake in Lewy body disorders
While PET dominates tau imaging, SPECT tau tracers are in development:
- Potential for broader accessibility
- Lower cost compared to PET
- Currently limited by resolution and sensitivity
¶ Limitations and Challenges
- Lower spatial resolution compared to PET
- Radiation exposure (though lower than PET with some tracers)
- Quantification challenges due to partial volume effects
- Limited tomographic reconstruction compared to modern PET
- Cannot definitively diagnose specific disorders (only supports clinical impression)
- Overlap in patterns between different disorders
- Variable inter-operator and inter-site reliability
- Limited sensitivity in early disease stages
- Development of newer tracers with improved targeting
- Hybrid SPECT/CT and SPECT/MRI systems
- Quantitative SPECT with standardized uptake values
- AI-assisted interpretation for improved accuracy